# EDGAR Filing Document

**Accession Number:** 0001601830
**File Stem:** 0001601830-26-000043
**Filing Date:** 2026-2
**Character Count:** 19885
**Document Hash:** 1483e04f6e3ecc4c67a8817497337624
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001601830-26-000043.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0001601830-26-000043

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260225

**DATE AS OF CHANGE**: 20260225

**EFFECTIVENESS DATE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RECURSION PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001601830
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464099738
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293714
- **FILM NUMBER:** 26674161

**BUSINESS ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101
- **BUSINESS PHONE:** (385) 269-0203

**MAIL ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Recursion Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20140305

**As filed with the Securities and Exchange Commission on February 25, 2026**

**Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

<u><br></u>

**FORM S-8**

**REGISTRATION STATEMENT**

**Under**

**The Securities Act of 1933**

<u><br></u>

**RECURSION PHARMACEUTICALS, INC.**

**(Exact name of Registrant as specified in its charter)**

<u><br></u>

---

| | |
|:---|:---|
| **Delaware** | **46-4099738** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification Number)** |

---

<u><br></u>

**41 S Rio Grande Street**

**Salt Lake City, UT 84101**

(Address of principal executive offices, including zip code)

<u><br></u>

**2021 Equity Incentive Plan<br>2021 Employee Stock Purchase Plan**

(Full title of the plans)

<u><br></u>

**Najat Khan**

**Chief Executive Officer**

**Recursion Pharmaceuticals, Inc.**

**41 S Rio Grande Street**

**Salt Lake City, UT 84101**

**(385) 269-0203**

(Name, address and telephone number, including area code, of agent for service)

<u><br></u>

**Copies to:**

**Patrick J. Schultheis**

Wilson Sonsini Goodrich & Rosati,

Professional Corporation

701 Fifth Avenue, Suite 5100

Seattle, WA 98104

(206) 883-2500

<u><br></u>

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer" "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ☒ | Accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ |
| Non-accelerated filer&nbsp;&nbsp;&nbsp;&nbsp; ☐ | Smaller reporting company ☐ |
| | Emerging growth company ☐  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (this "Registration Statement") registers additional shares of Class A common stock of Recursion Pharmaceuticals, Inc. (the "Registrant") under its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan for which (i) a registration statement (No. 333-255315) on Form S-8 was filed with the Securities and Exchange Commission (the "Commission") on April 16, 2021; (ii) a registration statement (No. 333-264847) on Form S-8 was filed with the Commission on May 10, 2022; (iii) a registration statement (No. 333-271719) on Form S-8 was filed with the Commission on May 8, 2023; (iv) a registration statement (No. 333-279290) on Form S-8 was filed with the Commission on May 10, 2024; and (iv) a registration statement (No. 333-286963) on Form S-8 was filed with the Commission on May 5, 2025 (together, the "Previous Forms S-8"). Pursuant to General Instruction E to Form S-8, the contents of the Previous Forms S-8, including periodic reports filed after the Previous Forms S-8 to maintain current information about the Registrant, are incorporated by reference into this Registration Statement, except that the provisions contained in Part II of such earlier registration statement are modified as set forth in this Registration Statement.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the "Securities Act"), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

**PART II** 

**INFORMATION REQUIRED IN REGISTRATION STATEMENT** 

**Item 3.**&nbsp;&nbsp;&nbsp;&nbsp;**Incorporation of Documents by Reference.** 

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Registrant's Annual Report on <u>[Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183026000039/rxrx-20251231.htm)</u> for the fiscal year ended December 31, 2025 filed with the Commission on February 25, 2026 (the "Annual Report");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)The description of the Registrant's Class A common stock contained in the Company's Registration Statement on <u>[Form 8-A](https://www.sec.gov/Archives/edgar/data/1601830/000119312521112361/d146224d8a12b.htm)</u> (File No. 001-40323) filed with the Commission on [April](https://www.sec.gov/Archives/edgar/data/1620463/000095012320009608/atha-8a12b.htm) 12, 2021, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; *provided*, *however*, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

**Item 8.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| <br>**Exhibit**<br>**Number** | **Exhibit Description** | **Form** | **Incorporated by<br>Reference** | **Incorporated by<br>Reference** | **Filing Date** |
| | | | **File No.** | **Exhibit** | |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1601830/000119312521123764/d149444dex31.htm)</u> | 8-K | 001-40323 | 3.1 | April 21, 2021 |
| 4.2 | <u>[Amended and Restated Bylaws of the Registrant](https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/a1-25x24amendedbylaws.htm)</u> | 8-K | 001-40323 | 3.1 | January 31, 2024 |
| 4.3 | <u>[Specimen Class A common stock certificate of the Registrant](https://www.sec.gov/Archives/edgar/data/1601830/000119312521089610/d89478dex42.htm)</u> | S-1/A | 333-254576 | 4.2 | April 15, 2021 |
| <br>4.4 | <br><u>[2021 Equity Incentive Plan and forms of agreements thereunder](https://www.sec.gov/Archives/edgar/data/1601830/000160183023000010/exhibit103equityincentivep.htm)</u> | 10-K | 001-40323 | 10.3 | February 27, 2023 |
| <br>4.5 | <br><u>[2021 Employee Stock Purchase Plan and forms of agreements thereunder](https://www.sec.gov/Archives/edgar/data/1601830/000119312521112364/d89478dex104.htm)</u> | S-1/A | 333-254576 | 10.4 | April 15, 2021 |
| 5.1\* | <u>[Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation](ex51-wsgropinion2026sx8.htm)</u> |  |  |  |  |
| 23.1\* | <u>[Consent of Independent Registered Public Accounting Firm](exhibit231pwcconsentletter.htm)</u> |  |  |  |  |
| 23.2\* | Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in <u>[Exhibit 5.1](ex51-wsgropinion2026sx8.htm)</u> hereto) |  |  |  |  |
| 24.1\* | <u>[Power of Attorney (contained on signature page hereto)](#ib8baf6e210e344169f453018d9a276a5_16)</u> |  |  |  |  |
| 107\* | <u>[Filing Fee Table](exfilingfees.htm)</u> |  |  |  |  |

---

\*Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Salt Lake City, State of Utah, on February 25, 2026.

---

| | |
|:---|:---|
| **RECURSION PHARMACEUTICALS, INC.** | **RECURSION PHARMACEUTICALS, INC.** |
| By: | /s/ Najat Khan |
|  | *Najat Khan* |
|  | *Chief Executive Officer* |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Najat Khan and Ben Taylor, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all the said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

------

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Najat Khan<br>Najat Khan | Chief Executive Officer and Director *(Principal Executive Officer)* | February 25, 2026 |
| /s/ Ben Taylor<br>Ben Taylor | Chief Financial Officer *(Principal Financial and Accounting Officer)* | February 25, 2026 |
| <br>Zachary Bogue | Director | February 25, 2026 |
| <br>Blake Borgeson | Director | February 25, 2026 |
| /s/ Namandjé Bumpus<br>Namandjé Bumpus | Director | February 25, 2026 |
| /s/ Zavain Dar<br>Zavain Dar | Director | February 25, 2026 |
| /s/ Christopher Gibson<br>Christopher Gibson | Chair of the Board | February 25, 2026 |
| /s/ Robert Hershberg<br>Robert Hershberg | Vice Chair and Lead Independent Director of the Board | February 25, 2026 |
| /s/ Dean Li<br>Dean Li | Director | February 25, 2026 |
| /s/ Franziska Michor<br>Franziska Michor | Director | February 25, 2026 |
| /s/ Elaine Sun<br>Elaine Sun | Director | February 25, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Recursion Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Table 1 – Newly Registered Securities**

**CALCULATION OF REGISTRATION FEE**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type** | **Security Class Title** | **Fee Calculation** | **Amount<br>to be<br>registered**<sup>1</sup> | **Proposed<br>maximum<br>offering<br>price per Unit** | <br>**Maximum**<br>**aggregate**<br>**offering price** | **Fee Rate** | **Amount of<br>registration fee**<sup>(3)</sup> |
| Fees to be Paid  | Equity  | Class A Common Stock, $0.00001 par value per share, reserved for issuance under the 2021 Equity Incentive Plan | 457(c) and 457(h) | 16186000<sup>2</sup> | $3.445<sup>3</sup> | $55760770.00 | 0.00013810 | $7700.56 |
| Fees to be Paid  | Equity  | Class A Common Stock, $0.00001 par value per share, reserved for issuance under the 2021 Employee Stock Purchase Plan | 457(c) and 457(h) | 3238000<sup>4</sup> | $2.928<sup>5</sup> | $9480864.00 | 0.00013810 | $1309.31 |
|  |  |  | **Total Offering Amounts** |  |  | $65241634.00 |  | $9009.87 |
|  |  |  | **Total Fees Previously Paid** |  |  |  |  | 0 |
|  |  |  | **Total Fee Offsets** |  |  |  |  | 0 |
|  |  |  | **Net Fee Due** |  |  |  |  | $9009.87 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement covers any additional shares of the Registrant's Class A Common Stock that become issuable under the 2021 Equity Incentive Plan (the "2021 Plan") and the 2021 Employee Stock Purchase Plan (the "2021 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding shares of Class A Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Represents an automatic annual increase of 16,186,000 shares of Class A Common Stock on January 1, 2026 to the number of shares of the Registrant's Class A Common Stock reserved for issuance under, and which annual increase is provided for in, the 2021 Plan pursuant to an "evergreen" provision contained in the 2021 Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of $3.445 per share, which is the average of the high and low prices of the Registrant's Class A Common Stock on February 23, 2026, as reported on the Nasdaq Global Select Market.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.Represents an automatic annual increase of 3,238,000 shares of Class A Common Stock on January 1, 2026 to the number of shares of the Registrant's Class A Common Stock reserved for issuance under, and which annual increase is provided for in, the 2021 ESPP pursuant to an "evergreen" provision contained in the 2021 ESPP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of 85% of $3.445 per share, which is the average of the high and low prices of Registrant's Class A Common Stock on February 23, 2026, as reported on the Nasdaq Global Select Market. Pursuant to the 2021 ESPP, the purchase price of the shares of Class A Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of a share of Class A Common Stock on the last trading day prior to the first trading day of each offering period or on the last trading day prior to the exercise period.

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![image_1.jpg](image_1.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wilson Sonsini Goodrich & Rosati<br>Professional Corporation<br>701 5th Ave.<br>Suite 5100<br>Seattle, Washington, 98104<br>o: 206.883.2500 |

---

February 25, 2026

Recursion Pharmaceuticals, Inc.

41 S Rio Grande Street

Salt Lake City, Utah 84101

**Re: <u>Registration Statement on Form S-8</u>**

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "Registration Statement") to be filed by Recursion Pharmaceuticals, Inc., a Delaware corporation (the "Company"), with the Securities and Exchange Commission (the "Commission") on or about the date hereof, relating to the registration under the Securities Act of 1933, as amended (the "Act"), of an aggregate of 19,424,000 shares of your Class A common stock, par value $0.00001 per share (the "Shares"), consisting of: (i) 16,186,000 shares of Class A common stock to be issued under the 2021 Equity Incentive Plan (the "2021 EIP") and (ii) 3,238,000 shares of Class A common stock to be issued under the 2021 Employee Stock Purchase Plan (the "2021 ESPP," and together with the 2021 EIP, the "Plans"). As your legal counsel, we have reviewed the actions proposed to be taken by you in connection with the issuance and sale of the Shares to be issued under the Plans.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when issued and sold in the manner described in the Plans and pursuant to the agreements that accompany the Plans, will be legally and validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion as an exhibit to the above-referenced Registration Statement and to the use of our name wherever it appears in the Registration Statement and in any amendments thereto. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,

WILSON SONSINI GOODRICH & ROSATI

Professional Corporation

/s/ Wilson Sonsini Goodrich & Rosati, P.C.

AUSTIN BOSTON BOULDER BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO<br>SALT LAKE CITY SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Recursion Pharmaceuticals, Inc. of our report dated February 25, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Recursion Pharmaceutical, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP

Seattle, Washington

February 25, 2026

<br>